• Telehealth
• Compounding
• Legal

An ad watchdog told a telehealth seller to drop "personalized" claims for its compounded tirzepatide. What NAD decided, and why it matters

By Peptide Policy Watch staff · Published November 5, 2026 · Updated November 6, 2026 · 7 min read · 7 sources, 7 checked at the source

"Compounded for your unique needs" sounds like a promise about you. According to a decision released November 4, 2026, it was really a promise about a product, and the seller couldn't back it up. The National Advertising Division, the advertising industry's own watchdog, looked at how an online telehealth platform marketed a compounded tirzepatide blend after Eli Lilly challenged the ads. Here's what it found, what it didn't decide, and how it lines up with FDA's own push on GLP-1 marketing.

Facts are as of November 5, 2026. Sources, with retrieval dates, are at the bottom.

Who's who

Eli Lilly makes Mounjaro and Zepbound, which NAD's release describes as the only tirzepatide medicines approved by FDA, one for type 2 diabetes and one for long-term weight management. [V] Good Life runs an online platform that connects consumers with healthcare professionals and pharmacies, and it marketed compounded tirzepatide products under the name "Tirzepatide+." [V] Lilly challenged claims about the products' efficacy, safety, FDA status and personalization. [V]

The National Advertising Division was set up by the ad industry in 1971. It reviews national advertising when a competitor, a consumer or its own staff flags it. [V] Taking part is voluntary. But NAD says that when an advertiser refuses to participate or won't follow its recommendations, it refers the matter to the appropriate regulator, usually the FTC. [V]

The evidence problem

This is the part worth slowing down for. Good Life didn't show up empty-handed. NAD says it submitted "substantial clinical literature" on tirzepatide, separate studies on the added ingredients, a Gallup survey and retrospective cohort studies. [V] NAD still found none of it was "a good fit" for the claims, for three reasons:

• The tirzepatide research mostly concerned Lilly's FDA-approved products. [V]
• Nothing in the record connected ingredient-level research to Tirzepatide+ as an actual finished compounded product. [V]
• The survey and cohort studies didn't look at Tirzepatide+ at all. [V]

NAD also noted the record had no evidence about whether tirzepatide is safe when mixed with the added ingredients. And it said FDA allowing compounding during the drug shortages didn't count as support for the claims. [V] So the recommendation was to discontinue the express health claims, and to change the ads so they don't imply the product is safe and effective or delivers significant weight loss. [V]

That gap between an ingredient and a product shows up across this site. The big tirzepatide trials tested Lilly's medicine, made and checked under its approval. A compounded blend with extra ingredients is a different product, and nobody has run that trial. Our GLP-1 explainer lays out how approved, compounded and "research" products differ.

What "personalized" was supposed to mean

Lilly also went after the language that made the product sound made-to-order. NAD's view was that the ads overstated what actually happens. A prescriber may choose among available formulations and adjust a treatment plan over time, NAD wrote, but that's not the same as the product being made or formulated for one specific person. [V]

The legal backdrop helps explain why the word matters, even though NAD's release doesn't bring it up. [V] Under FDA's compounding guidance, a 503ASection of federal drug law covering compounding by state-licensed pharmacies and doctors, usually for a prescription written for one patient. Glossary entry pharmacy generally can't keep turning out near-copies of a drug that's already on the market. FDA treats a compounded product as a copy if it has the same ingredient in the same or a similar strength, unless a prescriber documents a change that makes a significant difference for an identified patient. [V] FDA has said that adding vitamin B12 to semaglutide can still count as a copy. [V] So "personalized" isn't just a marketing word in this market. It overlaps with the language of the legal exception. We're not saying NAD relied on that; its release doesn't say so. [U]

Not the first time, and not only NAD

Lilly has used this process before. In January 2025, Admire Aesthetics permanently dropped claims about its compounded tirzepatide with B12, including "superior" weight loss compared with Mounjaro. [V] In June 2025, Begin Anew MedSpa dropped claims that its tirzepatide-plus-B12 product was FDA approved and that its formula reduced nausea. [V] In both, NAD treated the dropped claims as though it had recommended discontinuing them. [V]

FDA is working the same territory with its own tools. In February 2026, the agency said companies can't call non-approved compounded products generic versions of approved drugs, the same as approved drugs, or clinically proven. [V] On October 30, 2026, FDA's compounding office sent a warning letter to RonanRx over website and X posts. The letter cited labels that suggested the firm was the compounder when it wasn't, and phrases like "FDA-Approved Compounded Medications" and "Well-Studied Compounded Medications." [V] FDA wrote that disclaimers saying a preparation "may not itself be FDA-approved" don't fix "the misleading overall impression." [V] The letter gives the firm 15 working days to respond. [V] Our marketing red flags guide collects these patterns in one place.

What this decision is, and isn't

• It's a recommendation about advertising claims, not a ruling on whether compounded tirzepatide can be prescribed. [V]
• It doesn't say the product is unsafe. It says the advertiser didn't have a reasonable basis for the claims it made. [V]
• Good Life also voluntarily and permanently dropped certain claims about clinical results, benefits, ingredients, safety and sourcing during the inquiry. [V]

Limits of what we can see

The full NAD decision sits in a paid archive; we worked from the public release. [V] That means we can't quote the exact ads, list which additives were in Tirzepatide+ or say how long the claims ran. [U] We also don't know whether Lilly has other NAD challenges pending. [U] And none of this is a finding by FDA or the FTC. [V]

Where it leaves things

Expect the words on these sites to keep changing. Between NAD cases, FDA warning letters and the February 2026 crackdown, "personalized," "FDA-approved ingredient" and "clinically proven" are the phrases drawing the most fire. Our pages on telehealth and compounding and Lilly's retatrutide enforcement track the same fight from other angles. If Good Life's ads change, or NAD posts another GLP-1 case, we'll add it here.

For a telehealth path that names the FDA-approved bottle rather than a compounded tirzepatide ad, see LifeMD's November 2026 claim that its pharmacy can dispense Lilly self-pay Zepbound and Foundayo — our brief stays on what the company said.

Sources (retrieved November 5, 2026)

1. BBB National Programs, "National Advertising Division Recommends Good Life Discontinue Health Benefit and Personalization Claims for Compounded Tirzepatide+ Products," NAD Case #7586, November 4, 2026 [V] — https://bbbprograms.org/media/newsroom/decisions/good-life
2. BBB National Programs, "National Advertising Division (NAD)" program page and FAQs [V] — https://bbbprograms.org/programs/all-programs/national-advertising-division
3. BBB National Programs, "In National Advertising Division Challenge Admire Aesthetics Voluntarily Discontinues Claims for Compounded Tirzepatide," January 23, 2025 [V] — https://bbbprograms.org/media/newsroom/decisions/admire-aesthetics
4. BBB National Programs, "In National Advertising Division Challenge, Begin Anew MedSpa Voluntarily Discontinues Claims for Compounded Tirzepatide," June 3, 2025 [V] — https://bbbprograms.org/media/newsroom/decisions/begin-anew
5. FDA, "FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs," February 6, 2026 [V] — https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs
6. FDA warning letter, RonanRx, Inc. dba RonanRx, MARCS-CMS 737905, October 30, 2026 [V] — https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ronanrx-inc-dba-ronanrx-737905-10302026
7. FDA, "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize," update of April 1, 2026 [V] — https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize

Spot a mistake? See how we source and our corrections policy.

Image: AI-generated. Image credits